var data={"title":"Poly-L-lactic acid: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Poly-L-lactic acid: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6801?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211254\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Sculptra;</li>\n      <li>Sculptra Aesthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211264\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Cosmetic Agent, Implant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211255\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Facial fat loss (lipoatrophy)</b> (Sculptra): Intradermal or SubQ: ~0.05-0.2 mL per individual injection depending on technique used; ~20 injections may be needed per cheek. Treatment should be individualized. Separate treatments by &ge;2 weeks. Typical course involves 3-6 treatments. Supplemental injections may be needed. Do not overfill contour deficiency. For patients with severe facial fat loss, the average treatment requires ~1 vial per cheek area per treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Facial wrinkles</b> (Sculptra Aesthetic): Intradermal: 0.1 to 0.2 mL per individual injection to a maximum of 2.5 mL per nasolabial fold as a single treatment; may repeat treatment at &ge;3 week intervals up to 4 times</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062216\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211240\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for suspension:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sculptra&reg;, Sculptra&reg; Aesthetic: Poly-L-lactic acid USP</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211232\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211242\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For injection into deep dermis or subcutaneous layer using tunneling, threading, or depot technique. Avoid intravenous injection. Space injections 0.5 to 1 cm apart. Administer using 26 gauge needle; do not bend needle. Occasionally agitate syringe during session to maintain a uniform suspension. Eliminate air prior to initial injection. Stretch skin prior to inserting needle. Massage treatment area in a circular motion after every 3 to 4 injections and for &ge;2 minutes at the end of the treatment session to evenly distribute. Do not fully correct or overcorrect. Local or topical anesthetic may be used prior to injecting. See prescribing information for detailed administration technique.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211241\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Facial fat loss (lipoatrophy):</b> Restoration and/or correction of the signs of facial fat loss (lipoatrophy) in patients with human immunodeficiency virus (HIV).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Facial wrinkles:</b> Correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles in immunocompetent patients </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211236\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Bruising (1% to 65%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic: Hematoma (up to 28%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Injection site: Edema (3% to 81%), tenderness (81%), redness (78%), pain (71%), papules (3% to 52%), bleeding (34%), pruritus (20%), nodules (3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Discomfort (up to 19%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Fever (&lt;5%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: erythema (up to 10%), injection site reactions (&lt;5%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Postmarketing/case reports: Allergic reaction, angioedema, brittle nails, colitis, ectropion, fatigue, hair breakage, hypersensitivity  reaction, hypertrophy, joint aches, malaise, periorbital nodules, photosensitivity, rash, scar/skin discoloration, skin infection, skin roughness, skin sarcoidosis, telangiectasia, urticaria, visible nodules </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Injection site reactions: Abscess, atrophy, discharge, fat atrophy, granuloma, induration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211245\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to poly-L-lactic acid or any component of the formulation; history or susceptibility to hypertrophic scarring or keloid formation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211234\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Injection-site reactions: Injection-site reactions including, bleeding, bruising, edema, erythema, and inflammation, have occurred within days to months after injection. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Photosensitivity: Patients should be instructed to limit exposure to excessive sunlight or UV lamps until any swelling or redness is resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders and patients on anticoagulant therapy; may have increased risk of hematoma, bleeding, or bruising at injection site.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin infection/inflammation: Patients with an active skin infection or inflammation skin eruptions (such as cysts, pimples, rashes, or hives) in or near the treatment area should not undergo treatment until the inflammatory or infectious process has been controlled. Treatment carries a risk of infection; utilize standard aseptic precautions during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Non-Caucasians: Safety and efficacy in non-Caucasians are limited.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Women: Safety and efficacy are limited in women with HIV.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Avoid IV injection; may lead to occlusion, infarction, or embolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Avoid use with implants. Avoid overcorrection of contour deficit; improvement occurs over weeks of treatment. Safety and efficacy have not been established for use in the lips or periorbital area. Safety and efficacy have not been established for use in larger amounts, at different frequencies, at sites other than deep dermis of nasolabial folds, with different techniques, or at sites with previous dermal fillers. Treatment for &gt;25 months has not been studied. Concomitant use with laser, chemical peeling procedures, or other procedure may increase risk of inflammation at the implant site, especially prior to complete healing of the skin. Sculptra Aesthetic has not been evaluated in immunocompromised patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced physician: Should be administered by an experienced health care provider who has appropriate training, experience, and knowledge of anatomy at injection site, and knowledge of aseptic technique.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Radiopaque: Patients should inform health care providers that they are receiving poly-L-lactic acid; microparticles of poly-L-lactic acid may be visible on CT scans, MRIs, ultrasound, or X-rays.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299902\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222419\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10301&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211247\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Reproduction studies have not been conducted. Safety for use in pregnant women has not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211248\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if poly-L-lactic acid is excreted in breast milk. Safety for use in nursing women has not been established. HIV-infected mothers are discouraged from breast-feeding to decrease potential transmission of HIV.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211233\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Poly-L-lactic acid is an immunologically inert synthetic polymer. It increases dermal thickness by causing a local reaction leading to an increase in collagen deposits. It is eventually degraded and undergoes resorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211244\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Onset of action: Weeks to months for full effect of treatment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26116693\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Sculptra Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">367.5 mg (2): $1,188.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Moyle GJ, Lysakova L, Brown S, et al, &ldquo;A Randomized Open-Label Study of Immediate Versus Delayed Polylactic Acid Injections for the Cosmetic Management of Facial Lipoatrophy in Persons With HIV Infection,&rdquo; <i>HIV Med</i>, 2004, 5(2):82-7. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/poly-l-lactic-acid-drug-information/abstract-text/15012646/pubmed\" target=\"_blank\" id=\"15012646\">15012646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sculptra aesthetic (injectable poly-L-lactic acid) [prescribing information]. Fort Worth, TX: Galderma Laboratories; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sculptra (injectable poly-L-lactic acid) [prescribing information]. Fort Worth, TX: Galderma Laboratories; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valantin MA, Aubron-Olivier C, Ghosn J, et al, Polylactic Acid Implants (New-Fill) to Correct Facial Lipoatrophy in HIV-Infected Patients: Results of the Open-Label Study VEGA,&rdquo; <i>AIDS</i>, 2003, 17(17):2471-7.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10301 Version 52.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F211254\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F211264\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F211255\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062216\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F211240\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F211232\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F211242\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F211241\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F211236\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F211245\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F211234\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299902\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222419\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F211247\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F211248\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F211233\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F211244\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F26116693\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10301|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}